|
市場調査レポート
商品コード
1373796
ジェネリック医薬品の世界市場 - 市場規模、シェア、成長分析：ブランド別、投与経路別- 業界予測（2023年～2030年）Global Generic Drugs Market Size, Share, Growth Analysis, By Brand (Pure and Branded), By Route(Administration, including oral) - Industry Forecast 2023-2030 |
||||||
|
|||||||
| ジェネリック医薬品の世界市場 - 市場規模、シェア、成長分析：ブランド別、投与経路別- 業界予測（2023年～2030年） |
|
出版日: 2023年10月18日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のジェネリック医薬品の市場規模は2021年に4,168億6,000万米ドルと評価され、予測期間（2023年～2030年）のCAGRは5.4%になるとみられており、2022年の4,393億7,000万米ドルから2030年には6,692億米ドルに成長する見通しです。
世界のジェネリック医薬品市場は、ブランド医薬品の特許切れ、ヘルスケア費用の上昇、より安価な治療選択肢の必要性などの要因により、著しい成長を遂げています。この成長の主な要因は、多くの大ヒット医薬品の特許が切れ、ジェネリック医薬品メーカーが競争してより低価格の必須医薬品を提供できるようになったことです。慢性疾患の増加により、費用対効果の高い治療オプションへの需要がさらに高まっている一方、各国の政府政策やヘルスケア構想は、特に新興経済圏において、ジェネリック医薬品へのアクセシビリティを高め、医療費を削減することを目指しています。また、医薬品の承認プロセスや規制の枠組みを合理化する取り組みも、市場の拡大を促進しています。しかし、世界のジェネリック医薬品市場には課題もあります。
心血管疾患、糖尿病、呼吸器疾患、がんなど、慢性疾患の世界の罹患率の増加が、費用対効果の高い治療オプションの需要に拍車をかけ、ジェネリック医薬品市場の需要増につながっています。
各国政府は、医療費の削減、重要な医薬品へのアクセスの向上、ジェネリック医薬品の採用促進を包括的な目標として、ジェネリック医薬品の利用を促進するための政策を制定し、イニシアチブを開始しています。こうした戦略には、ジェネリック医薬品の代替や価格規制といったメカニズムが関与しています。
ジェネリック医薬品業界は、多面的で厳しい規制環境に直面しており、ジェネリック医薬品メーカーは、先発医薬品との生物学的同等性の実証を必要とする複雑な承認手続きを巧みに通過しなければなりません。こうした規制上のハードルは、ジェネリック医薬品の市場導入を妨げ、メーカーの経費を増大させる可能性があります。
当レポートは、世界のジェネリック医薬品市場について調査し、市場の概要とともに、ブランド別、投与経路別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。
目次
エグゼクティブサマリー
親市場分析
市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 動向分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品分析
- マクロ経済指標
- トップ投資分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーター分析
世界のジェネリック医薬品市場、ブランド別
- 市場概要
- 純正薬、ブランド薬
世界のジェネリック医薬品市場、投与経路別
- 市場概要
- 経口投与
- 局所投与
- 非経口投与（注射）
- その他（吸入など）
- 経鼻
- 眼科用
世界のジェネリック医薬品市場、地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- 主要企業プロファイル
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Dr. Reddy's Laboratories Ltd.
- Lupin Limited
- Cipla Limited
- Hikma Pharmaceuticals plc
- AccordヘルスケアLtd.
- Aurobindo Pharma Limited
- Apotex Inc.
- Fresenius Kabi AG
- Zydus Cadila
- Glenmark Pharmaceuticals Ltd
- Torrent Pharmaceuticals Ltd.
- Amneal Pharmaceuticals, Inc.
- Bausch Health Companies Inc
- Alkem Laboratories Ltd.
- Aspen Pharmacare Holdings Limited
Global Generic Drugs Market size was valued at USD 416.86 Billion in 2021 and is poised to grow from USD 439.37 Billion in 2022 to USD 669.20 Billion by 2030, at a CAGR of 5.4% during the forecast period (2023-2030).
The global generic drugs market has seen remarkable growth due to factors like patent expirations of branded medications, rising healthcare expenses, and the need for more affordable treatment choices. This growth is primarily driven by the expiration of patents for many blockbuster drugs, enabling generic drug manufacturers to compete and offer lower-cost essential medications. The increasing prevalence of chronic diseases has further boosted the demand for cost-effective treatment options, while government policies and healthcare initiatives in various countries aim to enhance accessibility to generic drugs and reduce healthcare costs, particularly in emerging economies. Efforts to streamline drug approval processes and regulatory frameworks have also facilitated market expansion. However, the global generic drugs market encounters certain challenges.
Top-down and bottom-up approaches were used to estimate and validate the size of the global generic drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The global generic drugs market is segmented on the basis of brand, route, and region. By brand, the market is segmented into pure generic drugs and branded generic drugs. By route, the market is segmented into administration, including oral, topical, parental (injectable), and others (such as inhalation, nasal, and ophthalmic). By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers:
Increasing Chronic Diseases
The increasing worldwide incidence of chronic illnesses, including cardiovascular ailments, diabetes, respiratory issues, and cancer, is fueling the demand for cost-effective treatment options, leading to a rising market demand for generic drugs.
Government Initiatives
In numerous nations, governments are enacting policies and launching initiatives designed to encourage the utilization of generic medications, with the overarching goals of decreasing healthcare costs, enhancing access to vital drugs, and boosting generic drug adoption. These strategies involve mechanisms such as generic substitution and pricing regulations.
Restraints:
Complex Regulatory Environment
The generic drugs industry confronts a multifaceted and demanding regulatory environment, where generic drug producers must adeptly traverse intricate approval procedures that necessitate the demonstration of bioequivalence with branded medications. These regulatory hurdles have the potential to impede the market introduction of generic drugs and escalate expenses for manufacturers.
Perception and Trust Issues
Ensuring broader acceptance and adoption of generic drugs requires addressing the apprehensions of both patients and healthcare providers regarding the quality, effectiveness, and safety of generic medications when compared to their brand-name equivalents. To achieve this, it is imperative to establish trust and educate all stakeholders about the comparable quality and cost-effectiveness of generic drugs.
Market Trends:
Market consolidation in the pharmaceutical industry is on the rise, characterized by larger pharmaceutical companies either acquiring smaller generic drug manufacturers or forging strategic partnerships. This consolidation strategy is geared towards broadening product offerings, bolstering manufacturing capacities, and strengthening market presence.
There is a growing emphasis on biosimilars, generic versions of biologic drugs, as they gain momentum in both development and commercialization. These biosimilars are gaining significance in the worldwide generic drugs market by providing affordable alternatives to costly biologics.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Generic Drugs Market by Brand
- Market Overview
- Pure and Branded
- Global Generic Drugs Market by Route
- Market Overview
- Administration
- including oral
- topical
- parental (injectable)
- and others (such as inhalation
- nasal
- and ophthalmic)
- Global Generic Drugs Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Teva Pharmaceutical Industries Ltd. - Israel
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH (Novartis) - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. - Netherlands
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd. - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals plc - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accord Healthcare Ltd. - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc. - Canada
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals Ltd. - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd. - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc. - Canada
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd. - India
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aspen Pharmacare Holdings Limited - South Africa
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
